NCT06968481View on ClinicalTrials.gov

Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

April 30, 2026

Conditions
Post Partum Hemorrhage
Interventions
DRUG

Oxytocin

Sublingual oxytocin 1000 IU, 3000 IU or 6000 IU

DRUG

Oxytocin

Intramuscular oxytocin 10 IU

Trial Locations (1)

Unknown

Africa Center of Excellence for Population Health and Policy, Kano

Sponsors

Lead Sponsor

Insud Pharma
All Listed Sponsors
lead

Insud Pharma

INDUSTRY

NCT06968481 - Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage | Biotech Hunter | Biotech Hunter